While highly active antiretroviral therapy (HAART) has significantly reduced mortality rates in patients with human immunodeficiency virus type 1 (HIV-1), its efficacy may be impeded by emergence of drug resistance caused by lack of patient adherence. A therapeutic strategy that requires infrequent drug administration as a result of sustained release of antiretroviral drugs would put less burden on the patient. Long-acting antiretroviral prodrugs for HIV therapy were synthesized through modification of the active drugs, emtricitabine (FTC) and elvitegravir (EVG), with docosahexaenoic acid (DHA) in one-step, one-pot, high-yielding reactions. The in vitro drug release profiles of these synthetic conjugates demonstrated sustained and controlled release of the active drug over a period of 3-4 weeks attributable to the hydrolysis of the chemical linker in conjunction with the hydrophilicity of the parent drug. Both conjugates exhibited superior antiviral activities in tissue culture models of HIV replication as compared to those of the free drugs, strengthening their role as potent prodrugs for HIV therapy. Pharmacokinetic analysis in CD1 mice further confirmed the long-acting aspect of these conjugates with released drug concentrations in plasma detected at their respective IC 90 /IC 95 values over a period of 2 weeks and discernable amounts of active drug even at 6 weeks. Our findings suggest that the injectable small molecule conjugates could be used as long-acting controlled release of FTC and EVG in attempts to mitigate adherencerelated HIV resistance.
Introduction
Approximately 36.7 million people worldwide are affected by human immunodeficiency virus type 1 (HIV-1), of which 20.9 million receive highly active antiretroviral therapy (HAART; World Health Organization) (HIV/AIDS). Since the first antiretroviral, zidovudine, hit the market 32 years ago, there has been a steady growth of available treatment options (∼35 drugs) across seven distinct drug-classes, based on their molecular mechanism and resistance profiles (HIV/AIDS). Due to the increased number of currently available therapies, it has become even more imperative to tailor a treatment plan that addresses tolerability, safety, and convenience. Conventional antiretroviral therapy ineffective against suppressing HIV replication and can lead to the emergence of drug resistance (Paydary et al., 2013; Gross et al., 2001; Genberg et al., 2012) . In resource-constrained environments, especially with limited drug options, it becomes increasingly difficult to effectively address the development of acquired resistance and switch regimens in a timely manner (World Health Organization, 2010) . All these challenges underscore the need for long-acting therapeutics that can replace the daily pill burden by being administered on a more infrequent basis (Boffito et al., 2014) . Simplification of HIV therapeutic regimens can lead to improvement in patient adherence and make lifelong HIV management easier for the patients (Kerrigan et al., 2018) .
As an alternative to the more conventional oral HAART regimen, long-acting injectables (LAIs) can be administered on a more infrequent basis, reduce patient non-compliance, and potentially minimize the development of drug resistance (Owen and Rannard, 2016) . Although HIV-targeted injectable crystalline nanoparticle formulations have progressed to clinical trials, some concerns include prolonged systemic exposure and challenges in removing drug in the event of toxicity (Spreen et al., 2013) . Other drug nanoparticle formulations required multiple doses to achieve an enhanced pharmacokinetic (PK) effect over the corresponding soluble drugs (Gautam et al., 2013) . Attempts at encapsulating the active drugs into carriers have been limited by poor drug loading (Mandal et al., 2017) and "leaky" particles resulting from passive diffusion (Mandal et al., 2017; Tshweu et al., 2014) . Our lab has previously developed an injectable biopolymeric microconfetti delivery system for one week controlled release of saquinavir from a single injection (Collier et al., 2016) . However, a more sustained drug release profile is required to achieve fewer administrations to address the previously mentioned practical challenges faced in HIV therapy.
Direct chemical modification of an antiretroviral drug that transforms them into a LAI could circumvent the barriers that exist with the aforementioned injectable systems. To this end, we identified two current drugs with reactive functional moieties that can be used as chemical handles for further modification: emtricitabine (FTC) and elvitegravir (EVG). FTC, a nucleoside reverse transcriptase inhibitor (NRTI), was approved by the FDA in 2003 for the prevention and treatment of HIV infection in adults and children (Saag, 2006) . EVG, belonging to a different HIV drug class, integrase inhibitors, was FDAapproved in 2014 as a single pill formulation. EVG prevents HIV transmission by blocking an essential HIV enzyme required by the virus for integration of its genetic code into the host DNA (Unger et al., 2016) . Due to their high potencies, both drugs are part of several combination therapies that are currently being used worldwide by patients. However, their long-term efficacy is limited by daily administration (Truong et al., 2015) , poor bioavailability (Bastiaans et al., 2014) , and metabolism by cytochrome P450 3A4 (CYP3A4) (Klibanov, 2009) . LAI versions of these drugs could improve their systemic circulation and reduce the daily intake requirement, ultimately reducing the overall drug cost (Barnhart, 2017) . To realize this goal, we sought to develop two standalone LAI-based derivatives of antiretrovirals (FTC and EVG), with the potential for fewer drug administrations compared to traditional HAART therapy.
Herein, we report the synthesis of polyunsaturated fatty-acid (PUFA) modified-FTC and EVG as long-acting derivatives of the parent drugs. Success of this approach is dependent upon the cleavage rate of the chemical bond between the parent drug and the derivatizing moiety. We evaluated their antiviral activities against HIV-infected cells and compared to those of the free drugs. In vitro drug release profiles were generated in attempts to demonstrate sustained release of the active antiretrovirals. Pharmacokinetic analyses were also conducted in mice to discern the long-acting aspect of these drug conjugates.
Materials and methods

General considerations
Deuterated solvents were purchased from Cambridge Isotope Laboratories (Andover, MA, USA) and used without further purification. Compounds FTC-DHA and EVG-DHA were prepared according to literature procedures, with slight modifications. (Agarwal et al., 2013) All reagents were purchased from Sigma Aldrich (St. Louis, MO, USA) and used without further modification, unless otherwise indicated. Emtricitabine (FTC) was purchased from 1 ClickChemistry, Inc. (Kendall Park, NJ, USA). Elvitegravir (EVG) was purchased from PharmaBlock, Inc. (Sunnyvale, CA, USA). Reactions were performed under a dry nitrogen atmosphere, unless otherwise noted. All flash chromatography was carried out using a 75-mm inner diameter column containing 100-mm length of silica gel under a positive pressure of laboratory air. The following reagents were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: HIV-1 NL4-3 Infectious Molecular Clone (pNL4-3) from Dr. Malcolm Martin, TZM-bl from Dr. John C. Kappes, Dr. Xiaoyun Wu, and Tranzyme Inc. 7, 10, 13, 16, FTC (800 mg, 3.24 mmol), docosahexanoic acid (DHA) (2.13 gm, 6.47 mmol), and N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate, O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) (2.45 gm, 6.47 mmol) were dissolved in dry dimethylformamide (DMF, 20 mL) in a 100 mL round-bottom flask. Diisopropylethylamine (DIPEA) (18.6 mL, 0.11 mol) was added to the reaction mixture via a gas tight syringe, and the reaction was allowed to proceed for 18 h at room temperature. The reaction mixture was then concentrated under reduced pressure and purified by flash chromatography (50:50 v/v ethyl acetate/hexanes) to afford compound FTC-DHA as a colorless oil (1.18 gm, 65% yield). 7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl) 
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EVG (650 mg, 1.45 mmol), DHA (958 mg, 2.9 mmol), and HBTU (1.1 gm, 2.9 mmol) were dissolved in dry DMF (20 mL) in a 100 mL round-bottom flask. DIPEA (8.3 mL, 47.9 mmol) was added to the reaction mixture via a gas tight syringe, and the reaction was allowed to proceed for 18 h at room temperature. The reaction mixture was then concentrated under reduced pressure and purified by flash chromatography (50:50 v/v ethyl acetate/hexanes) to afford EVG-DHA as a pale yellow oil (1 gm, 91% yield). 
Hydrolytic release curves
The hydrolysis of FTC-DHA and EVG-DHA were studied at pH 7.4 (0.1 M phosphate buffered saline). All experiments were performed in triplicate. Each drug conjugate (1 mg/mL) was stirred continuously while being maintained at 37°C. At appropriate time intervals (1, 3, 7, 10, 14, 17, 21, 24, 28, 31, 35 , and 42 days) samples were withdrawn and UV absorbance was recorded (300 nm for free FTC released from FTC-DHA and 320 nm for free EVG released from EVG-DHA).
Antiviral activity in vitro
HIV-1 NL-43 was prepared by transfecting 293 T cells using ExpressFect (Denville Scientific) with NL4.3 provirus plasmid. (Kulkarni et al., 2017; Adachi et al., 1986 ) Transfected cells were incubated for 48 h at 37°C and the supernatant was collected, centrifuged at 400 × g for 5 min, and passed through a 0.45 μm filter. 1 × 10 6 HeLa-derived human TZM-bl cells, (Wei et al., 2002; Platt et al., 2009 Platt et al., , 1998 Takeuchi et al., 2008; Derdeyn et al., 2000) which contain a luciferase gene under the control of a HIV-1 promoter, were plated in each well of a 96 well plate and were incubated with 50 µL HIV-1 NL-43 along with serial dilutions of each compound. After 48 h at 37°C, culture supernatants were removed and cells were lysed using 100 μL of 1X Passive Lysis Buffer (Promega, USA) overnight at −80°C and three subsequent freeze-thaw cycles. Tat-induced luciferase reporter gene expression was measured in TZM-bl cells by luminescence produced via reaction with Bright-Glo™ reagent (Promega, USA) quantified on a Spectramax i3X (Molecular Devices, USA). Cells which have been successfully infected with HIV-1 NL-43 produce luciferase enzyme that reacts with Bright-Glo™ reagent, and therefore, viral infectivity correlates directly to luminescence.
Pharmacokinetic evaluation of FTC-DHA and EVG-DHA conjugates
CD-1 mice (female, 10-11 weeks old) were purchased from Charles River Laboratories (Wilmington, MA, USA). Free FTC drug solution (30 µL; 1 g/ml in PBS; 1000 mg/kg) was injected intramuscularly into the right leg of each mouse (n = 2) with collection time points of 1, 6, 12, 24, 36, 48, 72, 168, 240 , and 336 h. For the PK study using FTC-DHA, drug conjugate solution (22 µL; 1 g/mL in ethanol; 750 mg/kg) was injected intramuscularly into the right leg of each mouse (n = 3). Collection time points were 1, 6, 12, 24 h, 3, 7, 14, 21, 28, 35 , and 42 days post injection.
Free EVG drug solution (25 µL; 1 g/ml in ethanol; 1000 mg/kg) was injected intramuscularly into the right leg of each mouse (n = 1) with collection time points of 1, 6, 12, 24, 36, 48, 72, 168 , and 336 h. For the PK study using EVG-DHA, drug conjugate solution (19 µL; 1 g/mL in ethanol; 750 mg/kg) was injected intramuscularly into the right leg of each mouse (n = 1). Collection time points were 6, 24, 48 h, 7, 14, 22, 28, 35 , and 42 days post injection. At each time point for all the in vivo studies, whole blood was collected by submandibular bleeds followed by euthanasia of mice via CO 2 .
Plasma from both studies was obtained by centrifuging the whole blood samples in Greiner Bio-One MiniCollect capillary blood collection system tubes (Fisher Scientific, Hampton, NH, USA) for 10 min at 4000 × g in a Thermo Scientific Sorvall Legend Micro 21 microcentrifuge (Hampton, NH, USA) and stored at −80°C until LC/MS analysis.
LC/MS quantification of plasma samples
FTC and EVG were extracted from mouse plasma samples using a protein precipitation with isotopically-labeled internal standard (Emtricitabine 13 C,
15
N and Elvitegravir-d6, respectively). FTC was eluted from a Waters Atlantis T3 (2.1 × 100 mm, 3 μm particle size) analytical column using 0.1% formic acid in water (mobile phase A) and 0.1% formic acid in acetonitrile (mobile phase B). EVG was eluted from a Waters Atlantis T3 (2.1 × 50 mm, 3 μm particle size) analytical column using 10 mM ammonium acetate (mobile phase A) and acetonitrile (mobile phase B). Both analytes were detected on an AB Sciex API-5000™ triple quadrupole mass spectrometer. Standards and quality controls (QC) were prepared in duplicate, and a calibration curve was generated using a weighted linear regression of analyte:internal standard peak area ratio vs. concentration. FTC and EVG concentrations in QCs and study samples were calculated from this calibration curve using Sciex Analyst Chromatography Software. The acceptance criteria of the assay was ± 20% of nominal concentration for standards and QCs. The quantifiable ranges were 2-20,000 ng/mL (FTC) and 12.5-10,000 ng/mL (EVG).
Plotting and non-compartmental analysis (NCA) were performed using Phoenix WinNonlin v8.0 software. The sparse sampling function was applied for a composite NCA of concentration data from all animals. The linear trapezoidal rule was used to calculate AUC 0-42 d . The terminal elimination rate constant (k el ) was calculated by fitting a linear regression line to the observed terminal concentration versus time data on a semi-log plot. All values below the limit of quantification were imputed at half the lower limit of quantification (2 ng/mL) for analysis purposes. Steady-state PK parameter estimates included k el , t 1/2 (half-life), C max (maximal or peak concentration), and AUC 0-42 d (area under the steady-state plasma concentration-time curve over 42 days).
Results and discussion
Chemistry
FTC-and EVG-modified docosahexanoic ester conjugates were synthesized in simple one-step, one-pot, and high-yielding reactions (Scheme 1). Although similar chemistry has been previously reported with anti-HIV drugs lamivudine (Guo et al., 2017) ; FTC (Agarwal et al., 2013) , and abacavir (Singh et al., 2016) conjugated to myristic acid, multi-step syntheses with lower overall yields were required to obtain the desired compounds. Our strategy eliminated the need for additional synthetic manipulations and had improved yields. Taking advantage of the inherent chemical moieties in the antivirals and modifying them to yield prodrugs allows for complete drug incorporation when compared to methods that encapsulate drugs in carriers through physical loading (Ogunwuyi et al., 2016) . In designing these conjugates, there were two major components that required careful consideration: chemical linker and choice of PUFA. While there is a broad range of linkers to choose from, carboxylic ester-based ones are convenient since the precursors are widely applicable across many therapeutic platforms and do not need prior chemical modification (Nobs et al., 2004) . The ester bond is known to undergo slow hydrolysis when subjected to enzymatic cleavage under physiological conditions in vivo (Fukami and Yokoi, 2012) ; facilitating extended release of the active antiretroviral from the synthesized prodrugs.
One of the major complications in HAART is that some antiretrovirals have limited bioavailability due to metabolism via the cytochrome P450 (CYP) CYP3A4 in the intestine and the liver (Klibanov, 2009) . As a result, they typically require the drug to be co-administered with pharmacokinetic enhancers (Walubo, 2007; Ramanathan et al., 2007) . To minimize drug-drug interactions while maintaining therapeutic drug concentrations in plasma, we directed our efforts in identifying relevant candidates that allow the therapeutics to remain in the bloodstream for a longer time. PUFAs have been shown to inhibit drug-metabolizing CYP enzymes (Yao et al., 2006) , which can reduce the rate of metabolism of the active antiretrovirals. Of the available PUFA options, docosahexaenoic acid (DHA) was chosen because it demonstrated greater inhibitory potency against CYP3A4 (Yao et al., 2006) . Such competitive inhibition of the antiretroviral-CYP3A4 enzyme interaction could potentially boost the drug's concentration and bioavailability, resulting in an improved PK profile.
An added advantage of conjugating long fatty chains to the antiretrovirals is the increased partition coefficients (log P) compared to those of the unmodified drugs, leading to an enhanced lipophilicity of the resultant conjugate (Agarwal et al., 2013) . Through increased lipophilicity (log P > 5), the DHA conjugate can improve cell uptake (Irby et al., 2017) . Our calculations also confirmed that the fatty chainmodified conjugates have higher log P values (> 5) compared to their respective unconjugated drugs (< 5) ( Table 1) .
Cell-based antiretroviral activity
To evaluate the antiretroviral efficacy of the synthesized conjugates, TZM-bl cells were treated with indicated doses of free FTC, EVG, DHA, FTC-DHA, or EVG-DHA conjugates. PUFA-modified anti-HIV drugs exhibited higher activity against cell-associated virus than their corresponding parent drugs (Fig. 1) . FTC-DHA (IC 50 = 1.39 µM) was ∼12 times more potent than free FTC (IC 50 = 17.2 µM) alone, while EVG-DHA (IC 50 = 0.14 µM) was ∼220 times more potent than free EVG (IC 50 = 30.9 µM). Previously published myristoylated FTC conjugate has also been shown to have a higher anti-HIV activity (24 times) when compared to that of FTC alone, indicating that modification of the parent drug generated a more potent prodrug (Agarwal et al., 2013) . Another NRTI-lipid conjugate, abacavir-myristic acid, had comparable antiviral activity with its native form against monocyte-derived macrophages (Singh et al., 2016) . Our results clearly demonstrate that the PUFA derivatives of the antiretrovirals reported herein have enhanced antiviral activity as compared to that of the parent drugs. Scheme 1. Synthetic schemes of (a) FTC-DHA and (b) EVG-DHA conjugates. The yellow circle highlights the ester bond, allowing for the potential prolonged release of the active drug when subjected to physiological conditions. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.) Table 1 Calculated (calc.) partition coefficients for the free drugs FTC and EVG; free DHA; synthesized FTC-DHA and EVG-DHA conjugates. Chem3D 15.1 software was used for generating log P values.
Compound
Log P (calc.)
4.56 DHA (Docosahexaenoic acid) 7.48 FTC-DHA 7.29 EVG-DHA 13.14 S.A. Krovi et al. International Journal of Pharmaceutics 552 (2018) 371-377 
Drug release profile
Drug release kinetics were evaluated for the synthesized FTC-DHA and EVG-DHA conjugates. As mentioned previously, ester bonds are known to degrade over a longer period of time, preventing burst release of the antiretroviral (Acton et al., 2013) . Using the ester bond chemistry for our conjugates, we also demonstrated that FTC-DHA conjugate had a gradual and sustained drug release profile over a period of 21 days, while EVG-DHA demonstrated a slower drug release over a period of 30 days (Fig. 2) . We hypothesize that due to the hydrophobicity of the EVG drug compared to the more hydrophilic FTC (Table 1) , it may be releasing at a much slower rate (Fu and Kao, 2010) . At the terminal time point, the remaining aggregate was subjected to 1 H NMR analysis to determine if any drug remained. The NMR spectrum displayed peaks pertinent to only DHA, indicating 100% of the drug had been released (Figs. S7 and S8 in ESI †) . The slow and sustained release over several days that we observed with our conjugates is in contrast to entecavir (an antiretroviral used to treat hepatitis B virus (HBV) infection) fatty acid conjugate achieved through similar chemistry where a significant amount of active antiretroviral (15-41%) was released within the first hour (Ho et al., 2018) .
Pharmacokinetics
In vivo experiments were conducted to determine the pharmacokinetic profiles of the unmodified drugs and the free drug released from the synthesized conjugates in CD1 mice, when given as an intramuscular injection (Fig. 3) . The absence of any observable absorption phase in the pharmacokinetic profiles could be attributed to the rapid diffusion that small molecules are known to undergo. Absorption of the free drugs and their conjugates could have occurred prior to the first drug-plasma concentration detection time point (6 h). All treatment groups peaked at the initial time points followed by steady decline of the release rate of the active antiretrovirals in plasma over time for both the FTC-DHA and EVG-DHA conjugates. The drug concentrations sufficient to provide 90% inhibition of viral replication (IC 90 ) for FTC in plasma is 14 ng/mL (Molina et al., 2004) , whereas the IC 95 for EVG in plasma has been reported to be 45 ng/mL (Podany et al., 2017) , As is evident in Fig. 3 , both free versions of the drugs were cleared within 48 h post injection with an unexpected rise in plasma concentration for free FTC at day 7. We speculate that rates of drug absorption could vary from different parts of the muscle, leading to slightly higher levels of drug being detected in plasma at later time points. Despite this observed variation in drug-plasma concentration, all subsequent time points have drug concentrations below their respective IC 90 /IC 95 values. In stark contrast, the plasma concentrations at 2 weeks of FTC and EVG released from the synthesized conjugates exceeded their respective IC 90 and IC 95 antiviral activities. Analysis of plasma samples even at 6 weeks illustrated detectable amounts of active drug that had been released from the conjugates. Presumably, even higher plasma concentrations of the drugs could be achieved in humans due to the faster systemic circulation clearance rates in mice (Lin et al., 1999) .
Pharmacokinetic parameters k el (elimination rate constant) and t 1/2 (half-life) are indicative of the rate at which the active drug is cleared from the blood. Controlled release of the active drug from the FTC-DHA and EVG-DHA conjugates led to ∼4-fold and ∼65-fold improvements in the t 1/2 over their corresponding free drugs, respectively ( Table 2) . As the conjugates exhibit longer half-lives, their rates of elimination are significantly diminished when compared to their free drug counterparts. A higher C max (maximum plasma concentration) value correlates with the rate of drug absorption. Both of the free drugs have much higher C max values when compared to those of their conjugates with a rapid decline in drug concentrations, indicating that they are absorbed Fig. 1 . Antiviral activities of conjugates against HIV-infected cells. TZM-bl cells were treated for 48 h with µM doses of (a) free FTC, free DHA, and FTC-DHA conjugate; (b) free EVG, free DHA, and EVG-DHA conjugate and evaluated for intracellular viral activity, as measured by luciferase assay. Data are presented as mean ± standard deviation (n = 2). Fig. 2 . In vitro release profiles of free FTC and EVG from (a) FTC-DHA and (b) EVG-DHA conjugates, respectively. Drug release was performed at pH 7.4 in PBS at 37°C and drug concentration was determined using UV-vis spectroscopy. Data are presented as mean ± standard deviation (n = 3). S.A. Krovi et al. International Journal of Pharmaceutics 552 (2018) 371-377 quicker than their modified analogs. Rapid absorption and clearance of the free drugs renders them ineffective for long-term therapy, as it would require frequent dosing to maintain therapeutic concentrations. Our approach maintains consistent drug-plasma concentrations above the IC 90 or IC 95 attributable to gradual release of the active drug which could enable infrequent dosing, ultimately leading to improved patient adherence and clinical outcomes. Considering the long-term implications of HAART therapy (Dakin et al., 2006; Chariot et al., 1999; Ofotokun and Weitzmann, 2010) , long-acting injectables could have substantial benefits for HIV+ individuals.
Conclusion
We have reported the synthesis of injectable long-acting antiretrovirals to address the emergence of resistance due to patient noncompliance. The one-step, one-pot chemistry is modular and has been used to modify anti-HIV drugs from two different classes with DHA to obtain lipid drug conjugates. These prodrugs demonstrated a sustained drug release profile in vitro and in vivo due to the slow hydrolysis of the ester bond, which could lead to reductions in dose and frequency of administration. Additionally, the collaborative effort of DHA could also contribute to longer circulation, potentially improving therapeutic efficacy. This strategy transformed short-acting unmodified drugs with half-lives of a few hours to extended-release prodrugs with improved PK profiles. Due to the ease of chemical conjugation and sustained drug concentrations in plasma over at least two weeks, this approach is promising in its ability to deliver therapeutic doses of FTC and EVG for an extended period of time. Fig. 3 . Plasma concentrations of (a) FTC and (b) EVG following in vivo release from intramuscular injections of FTC-and EVG-DHA conjugates, respectively. Data for FTC-DHA are presented as mean ± standard deviation (n = 3); EVG-DHA data are presented as absolute values (n = 1).
Table 2
Comparison of the plasma pharmacokinetic parameters of the free versions of FTC and EVG to their PUFA-modified counterparts. Parameters include elimination rate constant (k el ), half-life (t 1/2 ), maximum plasma concentration (C max ), and area under the curve for the plasma concentration over 42 days Krovi et al. International Journal of Pharmaceutics 552 (2018) 371-377 
